Proteome Sciences Share Forecast, Price & News

GBX 5.03
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: GBX 5.03
50-Day Range
MA: GBX 4.26
52-Week Range
Now: GBX 5.03
Volume672,979 shs
Average Volume811,263 shs
Market Capitalization£14.83 million
P/E Ratio50.25
Dividend YieldN/A
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers. The company develops the technology for isobaric tandem mass tag (TMT) and TMTpro, and manufacture small, protein-reactive chemical reagents; and Elayta, a small molecule inhibitor of beta-amyloid interaction with synaptic receptors that modifies downstream signaling and provides neuroprotective effects. It offers SysQuant and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the most important factor; TMT Calibrator ?combines protein and fluid proteomics to identify tissue proteins with evidenced availability for peripheral detection; PD biomarker discovery; and TMT SRM and Immuno Assay for CDx biomarker validation. The company primarily serves pharmaceutical and biotechnology companies, including academic research. Proteome Sciences plc was incorporated in 1993 and is headquartered in London, the United Kingdom.
Proteome Sciences logo

Industry, Sector and Symbol

Industry Medical Laboratories & Research
Year FoundedN/A



Sales & Book Value

Annual Sales£4.75 million
Cash FlowGBX 0.70 per share
Book ValueGBX (1.10) per share



Market Cap£14.83 million
Next Earnings DateN/A
OptionableNot Optionable


Proteome Sciences PLC
March 25, 2021 |  barrons.com
Proteome Sciences PLCShs Stock , PMSNF
January 3, 2021 |  markets.businessinsider.com
October 10, 2020 |  au.finance.yahoo.com
Proteome Sciences Upgrades Core Products With New Reagents
July 1, 2019 |  www.morningstar.co.uk
Proteome Sciences Upbeat On Future After "Good" First Quarter
April 30, 2019 |  www.morningstar.co.uk
See More Headlines


Overall MarketRank

0.73 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
GBX 5.03
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRM News and Ratings via Email

Sign-up to receive the latest news and ratings for PRM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Proteome Sciences (LON:PRM) Frequently Asked Questions

What stocks does MarketBeat like better than Proteome Sciences?

Wall Street analysts have given Proteome Sciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Proteome Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Proteome Sciences' earnings last quarter?

Proteome Sciences plc (LON:PRM) released its quarterly earnings results on Monday, August, 10th. The company reported ($0.17) earnings per share for the quarter.
View Proteome Sciences' earnings history

How has Proteome Sciences' stock been impacted by COVID-19?

Proteome Sciences' stock was trading at GBX 3.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PRM shares have increased by 54.6% and is now trading at GBX 5.03.
View which stocks have been most impacted by COVID-19

Who are Proteome Sciences' key executives?

Proteome Sciences' management team includes the following people:
  • Dr. Ian H. Pike, Chief Scientific Officer & Exec. Director
  • Mr. Richard Paul Dennis, Chief Commercial Officer & Exec. Director (Age 62, Pay $165k)
  • Dr. Mariola Söhngen, CEO & Exec. Director (Age 60)
  • Mr. Stefan Fuhrmann, Interim Fin. Director
  • Dr. Josef Schwarz, Chief Compliance Officer
  • Mr. Glenn Barney, VP of Sales & Marketing
  • Victoria Birse, Company Sec.

Who are some of Proteome Sciences' key competitors?

What other stocks do shareholders of Proteome Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteome Sciences investors own include ValiRx (VAL), boohoo group (BOO), Mondi (MNDI), Petrofac (PFC), Lloyds Banking Group (LLOY), Falanx Group (FLX), Quanterix (QTRX), Centrica (CNA), CyanConnode (CYAN) and Eckoh (ECK).

What is Proteome Sciences' stock symbol?

Proteome Sciences trades on the London Stock Exchange (LON) under the ticker symbol "PRM."

How do I buy shares of Proteome Sciences?

Shares of PRM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Proteome Sciences' stock price today?

One share of PRM stock can currently be purchased for approximately GBX 5.03.

How much money does Proteome Sciences make?

Proteome Sciences has a market capitalization of £14.83 million and generates £4.75 million in revenue each year.

How many employees does Proteome Sciences have?

Proteome Sciences employs 25 workers across the globe.

What is Proteome Sciences' official website?

The official website for Proteome Sciences is www.proteomics.com.

Where are Proteome Sciences' headquarters?

Proteome Sciences is headquartered at Hamilton House, Mabledon Place, LONDON, WC1H 9BB, United Kingdom.

How can I contact Proteome Sciences?

Proteome Sciences' mailing address is Hamilton House, Mabledon Place, LONDON, WC1H 9BB, United Kingdom. The company can be reached via phone at +44-20-70432116.

This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.